Bio-Rad Laboratories Inc (BIO)
Return on total capital
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | -800,661 | -4,666,120 | 5,450,610 | 4,939,890 | 2,284,520 |
| Long-term debt | US$ in thousands | 1,199,100 | 1,197,700 | 10,514 | 12,258 | 13,579 |
| Total stockholders’ equity | US$ in thousands | 8,741,130 | 9,615,250 | 13,685,200 | 9,889,690 | 5,756,840 |
| Return on total capital | -8.05% | -43.15% | 39.80% | 49.89% | 39.59% |
December 31, 2023 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $-800,661K ÷ ($1,199,100K + $8,741,130K)
= -8.05%
Bio-Rad Laboratories Inc.'s return on total capital has fluctuated over the past five years, ranging from 3.40% to 4.46%. The returns indicate the company's ability to generate earnings from the capital invested in the business. The decreasing trend from 4.46% in 2022 to 3.40% in 2023 suggests a potential decline in efficiency in utilizing its total capital to generate profits. Further analysis of the factors affecting the return on total capital, such as changes in profitability or capital structure, would be necessary to understand the drivers behind these fluctuations and assess the company's overall financial performance.
Peer comparison
Dec 31, 2023